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This special issue of Regulatory Toxicology and Pharmacology contains 9 scientiﬁc papers from Philip
Morris International about the laboratory and 1 about early clinical investigation of a novel ‘Tobacco
Heating System’. The studies have employed conventional and a wide range of newer ‘omics and bio-
informatics techniques to seek and explore potential toxic actions of the inhalable vapour it generates.
The methods of study and display of results employed are considered to be a valuable guide and model
for wider application in other toxicological investigations because they are directed more to proximal
causes of effects than to the cruder distal end points revealed by conventional, empirical procedures. As
such they should be regarded as a paradigm for the applicability and accuracy of the testing and pre-
diction of toxic risks.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND li-
cense (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cigarette smoking has been known as a risk to human health for
many years and investigation of diseases in active and passive
smokers, the substances involved and the mechanisms of their ef-
fects have led to considerable advances in epidemiology, medicine
and in vivo toxicity testing and in vitro studies of causal mecha-
nisms. In a perverse way there has been some beneﬁt from the
grave harms produced to offset against the societal, ﬁnancial and
political impacts of smoking.
In the past ﬁfteen years or so potential ‘Modiﬁed Risk Tobacco
Products’ have been introduced in the expectation that those
whose addiction to nicotine to the diseases if they inhaled vapours
containing less or even none of the harmful substances generated
in conventional cigarettes reliant on the combustion of tobacco.
These materials have been developed by ingenious engineering to
minimise or avoid known risks and to comply with the require-
ments of various ofﬁcial agencies governing the availability and na-
ture of current and future tobacco products; see, for example, the
US Family Smoking Prevention and Tobacco Control Act. Public
Law No. 111e131 (June 22, 2009) and the Tobacco Products Direc-
tive of the EU (2014/40/EU). The best known type of new product
has been the e-cigarette in which various materials are heated in
such a way that there is no combustion, thus minimising produc-
tion of many dangerous substances, whilst still providing the phys-
ical experience and sufﬁcient nicotine to satisfy smokers who ‘vape’
with them.
The development and availability of the e-cigarette has led to a
major difference of opinion between ofﬁcial agencies and medical
academies in Europe and the USA, the former accepting that theyInc. This is an open access article uoffer real beneﬁts to smokers and the latter being opposed to
them and favouring only complete abstinence from cigarettes;
see, for example, Green et al. (2016), McNeill et al. (2015) and
Nutt et al. (2016). The controversy is more about overall beneﬁt
to smokers or its absence and there has been less direct consider-
ation of the potential harmfulness of particular substances or
groups of compounds and their effects to which users would be
exposed apart from some uncertainty about the position of nicotine
in the debate.
Consider how such a product e a tobacco product or some other
material and heating device e might be investigated in advance to
demonstrate whether it would deliver little if any of the complex
mixture of known harmful products whilst still providing enough
nicotine for customer satisfaction. A classical programme of testing
would involve many chemical and biochemical analyses, studies of
respiratory and other physiological effects, extensive inhalation
toxicity testing with detailed studies of the respiratory tract and
clinical evidence of tolerance and the absence of exposure to poten-
tially harmful substances. If those experiments were done in the
right way the results would be extrapolated to the human popula-
tion as a whole, including the passive smoker, and some more or
less conventional biomonitoring schemes could be devised to
explore exposure in the real world. In the more distant future
epidemiological surveys would be expected to demonstrate the ex-
pected fall in smokingeassociated diseases but that would be a long
way ahead and the picture would be confused by the serious prob-
lem of the air pollution our life style has caused. All that pro-
gramme would depend on the availability and adequate extent of
multiple, sophisticated analytical and other experimental tech-
nique, many equally applicable to in vitro and in vivo experimentsnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
A.D. Dayan / Regulatory Toxicology and Pharmacology 81 (2016) S15eS16S16and human samples to show the level of exposure to a very large
number of substances and to demonstrate the degree or absence
of relevant biological end points, such as DNA damage, reactive ox-
ygen species and their effects, inﬂammatory changes and muta-
tions in cells of the respiratory tree and elsewhere. That is a
paradigm of classical toxicological methodologies based on study-
ing diverse ﬁnal end points, which often cannot be correlated
with each other, and probably of having to try to extrapolate
different end-points to common proximal but remote causal
mechanisms.
Very considerable advances beyond this position are offered by
recent developments in cellular and molecular biology, such the
‘omics technologies and the broad data analytical possibilities of
bioinformatics. The 10 papers in this special issue of Regulatory Toxi-
cology and Pharmacology provide detailed reports of modern and
conventional experimental investigations and a brief clinical study
of a ‘Tobacco Heating System’ developed by Philp Morris Interna-
tional that display the power and additional value of the newer
over more conventional toxicological techniques. The company de-
serves thanks for its openness in publishing the work as it can be a
guide and stimulus to improvements in other areas of toxicological
investigations.
Their scientists have shown how diverse ‘omics techniques sup-
plemented by sophisticated data analyses and displays make it
possible to detect and follow not only complex secondary end point
effects due to toxic exposures, such as inﬂammation seen simplisti-
cally as inﬁltrating cells or levels of amarker in a body ﬂuid, but also
to assess the primary causal mechanisms and processes in consid-
erable detail. The breadth of the newer techniques makes broad
surveys possible that can detect and reveal the detailed nature of
many toxic actions and cellular responses and so to show what
would be worth measuring to provide the earliest indication of a
toxic action. As many of the samples and procedures are as appli-
cable to laboratory experiments as to samples from humans they
offer the possibility of developing very sensitive and quantitative
monitoring of exposed people. Given quantitative results of these
types dose-response analysis should become feasible based on
real life circumstances rather than indirect extrapolations and
that should support more rigorous prediction of toxic risks than
can now be done based on current pragmatic observations.
2. Conclusions
The basic importance in toxicology of the newer procedures and
analyses is that they can reveal primary effects and their mecha-
nisms instead of the more conventional end-points, which can
only represent the net balance of complex distal or even terminal
actions and reactions involving different cellular mechanisms at
different times and stages. It is true that over the past 150 yearswe have learnt ways inwhich empirical observations of end effects,
such as tumour formation or altered metabolic pathways, can prag-
matically be related to overall measures of exposure and dose, but
how much safer and more reliable it will be to be able to relate ex-
posures to primary effects and consequential lesions. And, themore
accurate and focused information about pathogenic processes
should support more precise quantiﬁcation of harms and hence
more accurate prediction of risk.
The programme of studies published here by PhilipMorris Inter-
national may not yet go quite so far but it does display the potential
and indicates how it might be achieved. The body of their workmay
not be unique but it is very unusual to be able to follow such a
comprehensive account of investigations and results. As such it
can properly be regarded as a guide and goad to stimulate toxicol-
ogists and others and a presentation of real value to the toxicolog-
ical community.
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